VanEck Pharmaceutical ETF
PPH
62 hedge funds and large institutions have $195M invested in VanEck Pharmaceutical ETF in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 18 reducing their positions, and 1 closing their positions.
1,100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 1
95% more capital invested
Capital invested by funds: $99.9M → $195M (+$94.8M)
27.74% more ownership
Funds ownership: 26.88% → 54.62% (+28%)
19% more funds holding
Funds holding: 52 → 62 (+10)
6% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$49.8M |
| 2 |
Morgan Stanley
New York
|
+$25.2M |
| 3 |
Jane Street
New York
|
+$5.54M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$4.27M |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$794K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$698K |
| 3 |
OC
Oppenheimer & Co
New York
|
-$331K |
| 4 |
SWA
SFMG Wealth Advisors
Plano,
Texas
|
-$216K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$199K |
PPH Hedge Fund Activity: Q2 2015 in Review
62 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2015, worth a combined $195M — up 95% from $99.9M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PPH positions and 1 closed out — a net gain of 11 holders — while 19 added to existing stakes and 18 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $49.8M. The largest seller was Virtu Financial, exiting entirely with an estimated $794K sold.
- 62 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2015, up from 52 in Q1 2015.
- Funds reported $195M of VanEck Pharmaceutical ETF stock for Q2 2015, up 95% quarter-over-quarter.
- 12 funds opened new VanEck Pharmaceutical ETF positions in Q2 2015 and 1 closed out, a net change of +11 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2015 was Goldman Sachs, an estimated $49.8M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2015 was Virtu Financial, an estimated $794K sold.
Based on aggregated 13F filings for Q2 2015.